在伴有FLT3突变的复发难治性（R/R）急性髓系白血病（AML）中，吉瑞替尼联合用药真正使谁获益：一项加拿大单中心分析。
Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.
作者信息
Rajendra Akhil, Smith Elliot, Perusini Maria Agustina, Tang Kenny, Atenafu Eshetu G, Bankar Aniket, Chan Steven, Davidson Marta B, Gupta Vikas, Maze Dawn, Minden Mark D, Richard-Carpentier Guillaume, Schimmer Aaron D, Schuh Andre C, Yee Karen, Sibai Hassan
机构信息
Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
出版信息
Blood Cancer J. 2025 Aug 26;15(1):143. doi: 10.1038/s41408-025-01353-2.
Abstract
[Image: see text]
摘要
[图片：见正文]
Zotero 插件